Strategic Partnerships Azurity is actively pursuing exclusive commercial partnerships for D-PLEX100 in the U.S. and Canada with PolyPid, and is engaging in partnerships with Nang Kuang Medicine Trading Limited for respiratory therapies in China. This indicates ongoing collaboration-expand opportunities and regional channel strategies that a sales approach can align with.

Global Growth Drive With a portfolio of over 50 medicines across 10 therapeutic areas and presence in more than 50 countries, Azurity demonstrates a broad international expansion trajectory that can be leveraged to propose cross-portfolio value, regional distribution deals, and early-access programs in emerging markets.

Private Funding Momentum Recent investment by Audax Group alongside other investors signals strong capital backing for growth initiatives. This translates to potential for large-scale collaborations, co-development opportunities, and access to financed initiatives for joint go-to-market programs.

Manufacturing Footprint Consolidation The closure of the Wilmington facility and related layoff activity suggest ongoing optimization of manufacturing assets. This presents opportunities to offer manufacturing services, supply-chain optimization, or contract manufacturing partnerships to support remaining and future product lines.

D-PLEX100 Commercialization Readiness Upcoming launch of D-PLEX100 in early 2027 and exclusive commercialization agreements imply a near-term demand generation window. Sales outreach can focus on channel partners, distributors, and payer strategies to accelerate market access, reimbursement support, and patient access programs around this therapy.